Significant technological developments in testing landscape are offering favourable opportunities for market growth.
Traditional methods such as invasive endoscopic procedures and biopsy-based testing are being supplemented or replaced by non-invasive techniques such as serology, urea breath tests (UBT), and stool antigen tests (SAT). These advancements enhance patient comfort, reduce procedural risks, and improve diagnostic accuracy.
Additionally, recent improvements in urea breath tests include enhanced sensitivity and specificity, reducing false-positive and false-negative results. Advanced isotopic and non-isotopic UBTs offer quicker results and improved patient convenience.
Moreover, PCR-based methods detect H. pylori DNA directly from clinical samples. Recent advancements in PCR technology have reduced turnaround times and increased sensitivity, making them valuable tools in both diagnosis and monitoring treatment response.
Furthermore, POC tests for H. pylori offer quick results within minutes, allowing healthcare providers to diagnose and initiate treatment during the same visit. These tests are particularly beneficial in resource-limited settings and emergency departments.
The companies are actively involved in development and introduction of technologically advanced testing products, which is further expected to have positive impact on market growth during the forecast period.
Authors:
Mariam Faizullabhoy , Gauri Wani
Frequently Asked Questions (FAQ) :
Helicobacter pylori testing industry size was USD 483 million in 2023 and will grow at 6.8% CAGR between 2024 and 2032, driven by the increasing prevalence of H. pylori infections and advancements in diagnostic technologies.
Helicobacter pylori testing market from the diagnostic laboratories segment will reach USD 390.9 million by 2032, primarily due to their comprehensive testing capabilities and advanced diagnostic technologies.
North America helicobacter pylori testing industry will record 4.3% CAGR through 2032, propelled by the region's advanced healthcare infrastructure, high prevalence of gastrointestinal disorders, and significant investments in medical research and diagnostics.
Some of the prominent helicobacter pylori testing industry players are Abbott Laboratories, Advance Pharma, Avanos Corporate, Bio-Rad Laboratories, Inc., Cardinal Health, Inc., Epitope Diagnostics, Gulf Coast Scientific, Laboratory Corporation of America, Inc., Medline Industries, Meridian Biosciences, Inc., and Quidel Corporation, among others.